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A REVIEW OF CK2 EXPRESSION PATTERNS AND FUNCTION IN CANCERS 
HUSSEIN ABDULRASSOUL 
ABSTRACT 
 Over the past few decades numerous proteins and molecules have been 
discovered to be involved in the generation and/or progression of tumors in differing 
tissues. The ubiquitous serine/threonine kinase CK2 is such a protein. Previously it was 
shown that the dysregulation of CK2 transcript expression occurred in the most common 
cancers. Here we explore whether or not this is the case in less common cancer tissues. It 
was shown that dysregulation of CK2 expression did occur in lesser common cancer 
types. Interestingly, differing patterns of dysregulation were prevalent in differing tissue 
types. Some cancer types exhibited upregulation of all three CK2 transcripts, some 
tissues show mixed regulation of CK2 transcripts in which some genes were 
overexpressed and some were underexpressed, and in some tissue types all CK2 gene 
transcripts were underexpressed. This data, together with the known functions and roles 
of CK2 in cancer, demonstrate that CK2 may be a good diagnostic cancer biomarker.  
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INTRODUCTION 
CK2 Structure and Genes 
CK2 is a ubiquitous serine/threonine kinase that has widespread actions and has 
been implicated in a plethora of diseases such as inflammation conditions, cardiac 
hypertrophy multiple sclerosis, and most notably cancer {1-4}. The actions of CK2 are 
diverse and mediated through phosphorylation of potent downstream effector proteins 
such as β-catenin and Akt. CK2 is a member of a conserved serine/threonine kinase 
family found in mammals.  
CK2 is known to be transcribed from of two genes CK2α and CK2α’, with CK2α 
known to have higher and more widespread expression than CK2α’ {5}. There are two 
forms in which CK2 can function either a monomeric kinase, or as a tetrameric complex 
composed of two CK2α kinases subunits and two CK2β regulatory subunits, with the 
CK2β subunits determining substrate specificity {6}. Additionally, it should also be 
noted that a CK2α pseudogene (CK2αP) also exists, which is transcribed but never 
translated in humans, but it may be worth looking into in order to see if it is relevant in 
differing cancer types. 
CK2 Functions Through Other Signaling Molecules 
CK2 is involved in numerous essential cellular processes. In particular, CK2 
increases cell growth, cell proliferation, cell survival, cell morphological alterations, cell 
transformation and angiogenesis {7-13}. Although CK2 is known to be involved in these 
many processes, the molecular underpinnings of these effects are often poorly 
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understood. One of these reasons for this lack of understanding is the limited number of 
in vivo experiments performed to date and the limited studies in mutant mouse models.  
Although the CK2 molecular mechanisms can be complex and poorly understood, 
there are some pathways in which the CK2 and its cellular functions are more thoroughly 
understood. Two such pathways in which CK2 is involved in include Wnt signaling and 
Hedgehog signaling (Hh) {14,15}. For example, CK2 can activate Wnt signaling by 
phosphorylating and upregulating the transcriptional co-factor, β-catenin {14}. β-catenin 
is a transcriptional activator that leads to increased expression of proteins that promote 
cell proliferation, among others. In this way it can be seen how CK2 can indirectly exert 
its abilities in increasing cellular proliferation. Other signal transduction cascades in 
which CK2 has been seen to be linked with include such as JAK/STAT, NF-κB, 
PTEN/PI3K/Akt-PKB (figure 1) {16-20}. Therefore it is often proposed that CK2 can 
modulate and regulate cellular functions through many signaling cascades.   
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Figure 1. CK2 Molecular Pathways. Common pathways in which CK2 is activated and 
exerts its effects. In this specific figure it shows pathways involved in glioblastoma 
development (21).   
CK2 in cancer and signal transduction pathways 
As discussed before CK2 is involved in cellular proliferation, growth, survival, 
and even angiogenesis. These functions are often seen as markers for a protein with 
oncogenic potential. In fact, when CK2 is aberrantly overexpressed in mice; CK2 
functions as an oncogene {22-23}. CK2’s ability to promote tumors in animal models 
may be largely due to its ability to phosphorylate transcription and translational factors 
and subsequently manipulating gene expression. For example, one of the factors 
identified above that CK2 can regulated is NF-κB, has been demonstrated to be an anti-
apoptotic factor in breast tissue thus promoting breast cancer {24}.  Activation of 
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oncogenes is not the only method by which CK2 can promote tumorigenesis. For 
instance, the inactivation of PTEN, a tumor suppressor phosphatase, is another means by 
which CK2 has been implicated as an oncogene {20,25}.  CK2 has also been implicated 
as a stabilizer of other known proto-oncogene such as myc {26}. Conversely, CK2 itself 
is also regulated by other tumor-promoting oncogenes such as Bcr-Abl {27}. 
CK2 protein is found upregulated in a number of human tumors and it was 
proposed that this increase was due to a posttranslational mechanism{28-29}. However, a 
previous study on the cancers with the heist prevalence and fatality rate United States 
found that CK2 transcript expression was upregulated, suggesting that transcriptional 
mechanisms could also a culprit in the increase in CK2 protein {30). Unexpectedly, some 
tumors showed underexpression of certain CK2 genes (Table 1). For example it was 
observed that CK2α’ expression in breast, ovarian, and pancreatic cancer tissues were 
shown to be lower than those of normal breast, ovarian, and pancreatic tissues. 
Importantly, it was shown that these observed deregulations in CK2 gene expression 
correlated with patient survival and how aggressive certain cancer could be.  
These observations raised the question whether or not other cancers types showed 
significant CK2 gene expression differences as well. Therefore, we compiled the 
expression of CK2 genes in all other cancers including bladder, brain and central nervous 
system (CNS), esophageal, gastric, head and neck, kidney, blood (leukemia, non-
Hodgkin lymphoma, myeloma), liver, skin, mesothelioma, and testicular. We also review 
the literature on the signaling cascades that CK2 can be activating in each of these cancer 
types. 
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Table 1. CK2 Gene Expression In Prevalent Cancers Relative To Normal Tissues.  
Shows the relative CK2 in the most prominent forms of cancer {30}.  
	  6 
DATA ACQUISITION   
Oncomine Analysis 
 In order to determine the expression levels of CK2 in the different cancer types, 
the open source Oncomine database was used. The mRNA transcript level of both CK2 
genes, the CK2β gene and the CK2α pseudogene were extracted from the Oncomine 
database. The level of CK2 gene mRNA in clinical specimens of cancer and normal 
patient datasets were compared. To reduce false discovery rate, p < 0.01, fold change > 
+/- 1.5 were selected as threshold. Every cancer subtype was analyzed for p-values and 
fold change. 
 
Kaplan-Meier Plotter Analysis 
 The prognostic value of the CK2 genes in gastric cancer was determined by using 
a Kaplan-Meier Plotter website. (http://kmplot.com/analysis). This is a database that can 
correlate gene expression and clinical outcomes such as survival. Patients were split into 
two groups, higher versus lower expression levels of each CK2 gene, and were compared 
using the Kaplan-Meier survival plotter. Best specific probes (JetSet probes) were 
selected for each gene. To reduce false discovery rate, a p < 0.01 was selected as 
threshold. We used confidence intervals of 95% and subsequently calculated log rank p 
value.  	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RESULTS AND DISCUSSION 
Bladder Cancer 
Transitional cell carcinoma, also known as urothelial carcinoma, is by far the 
most prevalent form of bladder cancer and originates in the inner most layer of cells of 
the bladder. This type of bladder cancer is further subdivided clinically into superficial 
and invasive tumors. Less common bladder cancer types include squamous cell 
carcinoma and adenocarcinoma. There is no standard or routine screening test for bladder 
cancer, leading to a low rate of diagnosis before metastasis. Treatments for bladder 
cancer include common cancer treatments such as surgery, radiation, and chemotherapy. 
CK2 in Bladder Cancer 
Oncomine extracted data revealed significant overexpression of all three CK2 
transcripts in both superficial and invasive subtypes of bladder transitional cell carcinoma 
(Table 2). There were no significant results were found for CK2αP. Furthermore there 
was no data found for squamous cell carcinoma and adenocarcinoma, possibly due to the 
relative infrequency. Similar to the data collected, a recently study implied that CK2α 
protein may be overexpressed in bladder transitional cell carcinoma, particularly in 
invasive tumor subtypes {31}. Furthermore, exosomes, cell-derived extracellular 
vesicles, of metastatic bladder transitional cell carcinoma had also shown increased levels 
of CK2α protein {32}. This is relevant because exosomal release has been proposed to 
facilitate invasion and metastasis. Therefore this data may indicate a possible role for 
CK2α in bladder cancer metastasis. 
A marker of bladder cancer seems to be a the deregulation of cyclooxygenase 2 
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levels, COX2, in which the increased COX2 levels have show increased proliferation of 
superficial bladder cells and tumorigenesis {31}. This link between COX2 and cellular 
proliferation may is proposed to be induced by CK2. COX2 is an upstream molecule of 
CK2α, which subsequently leads to Akt activation and urokinase plasminogen activator 
(uPA) induction. It was shown that when inhibiting COX2 in bladder cells this CK2 
dependent activation of Akt and uPA was halted. This resulted in cell cycle arrest and 
decreased cellular proliferation {31}. Akt is itself a β-catenin activator, which is, as 
described before, a possible mechanism of induced cell growth {33}. And uPA has a 
multitude of functions, including the remodeling of extracellular matrix, and decreasing 
cellular adhesion Therefore CK2 has the potential to increase cellular proliferation and 
movement, leading to tumorigenesis and metastasis. Furthermore, a CK2α knockdown in 
bladder tissue with CK2α-siRNA showed a decrease in bladder cell proliferation and 
subsequently tumorigenesis as expected{34}. 
Table 2. – Relative Differences in CK2 mRNA expression in bladder cancer. 
Different subtypes of bladder cancer are analyzed and p-values, fold changes, and 
datasets are included {35-36}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Superficial Bladder Carcinoma 
CK2α 2.26 10-14 2.044 5% Sanchez-Carbayo 
Bladder 2 
157  
3.70 10-10 1.635 1% Dyrskjot Bladder 3 60  
CK2α’ 4.17 10-6 1.775 9% Dyrskjot Bladder 3 60  
 1.24 10-5 1.635 24% Sanchez-Carbayo 157  
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Bladder 2 
CK2β 2.65 10-17 2.874 3% Sanchez-Carbayo 
Bladder 2 
157  
7.38 10-8 2.010 3% Dyrskjot Bladder 3 60  
Invasive Bladder Carcinoma 
CK2α 9.15 10-8 1.696 7% Sanchez-Carbayo 
Bladder 2 
157  
2.33 10-5 1.583 7% Dyrskjot Bladder 3 60  
CK2α’ 0.003 1.501 25% Dyrskjot Bladder 3 60  
CK2β 1.48 10-7 2.211 1% Dyrskjot Bladder 3 60  
 0.001 1.420 21% Sanchez-Carbayo 
Bladder 2 
157  
Brain and CNS cancer 
The most common brain and CNS cancer type is glioma, which is sub-classified 
into astrocytomas, oligodendrogliomas, ependymomas, and mixed gliomas. A high-grade 
astrocytoma is known as glioblastoma. In adults, meningiomas are the most common 
brain and CNS cancers. Other tumor types include, but are not limited to, 
medulloblastomas, gangliogliomas, schwannomas, and craniopharyngiomas. There are 
currently no standard screens for brain and CNS cancers. Standard treatments involve 
watchful waiting, surgery, radiation, and chemotherapy.  
CK2 in Brain and CNS cancer 
As expected Oncomine analysis revealed an overexpression of CK2α transcripts 
in astrocytoma, glioblastoma, and anaplastic oligoastrocytoma (Table 3). This confirms 
the results obtained by Zheng et al., which showed CK2α transcript overexpressed in 
glioblastoma, which was attributed to “gene dosage gains” in CSNK2A1, the gene 
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encoding CK2α {37}. Oncomine analysis also showed overexpression of CK2α’ 
transcripts in astrocytoma and anaplastic oligoastrocytoma, and underexpression in 
glioblastoma and anaplastic oligodendroglioma. Therefore the overexpression of the 
CK2α gene but not the CK2α’ gene is more consistent in CNS cancers. This may 
correlate with the observation made by Ceglia et al, in which it was seen in mammalian 
brain that the CK2α gene is expressed much more than its sister CK2α’ gene {38}. All 
CNS and brain cancer types analyzed in this study revealed an overexpression of CK2β 
transcripts. However, there was a conflicting finding for glioblastoma as the Lee et al. 
study showed decreased expression of CK2β {39}. This may be in part due to the 
different methodologies used in these studies, with the Shai et al. study using frozen 
tumor samples, and the Lee et al. study using fresh tumor samples {40}{39}. For all 
other brain and CNS cancer subtypes, oncomine analysis showed no significant findings 
for any of the CK2 transcripts and CK2αP. In addition to the increased transcript 
expression demonstrated, CK2α protein expression levels were also upregulated in 
glioblastoma {41}. 
CK2α has been shown to increase cellular proliferation in the CNS by potentiating 
β-catenin.  In these CNS cancers it was shown that β-catenin regulates two genes 
involved in glioblastoma-initiating cell growth, Oct4 and Nanog. Both of these genes are 
involved in embryonic development and deregulation in adult tissues promotes tumors.  
Indeed, CK2α loss showed a decrease in Oct4 and Nanog, and subsequently a decrease in 
cell growth of glioblastoma tumor cells {41}. In addition, administration of an oral CK2 
inhibitor in glioblastoma cell lines led to not only increased apoptosis and G2-M phase 
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cell cycle entry but also decreased adhesion and migration. This suggests CK2 is 
involved in tumorigenesis and metastatic ability of CNS tumors. These cellular effects 
were demonstrated to be correlated with dysregulation in JAK/STAT-3, NF-κB, and 
PI3K/Akt pathways, as these pathways were hindered when CK2 was inhibited or 
knocked-out {37}. Similar results were found in glioma cells, where inhibition of CK2 
led to increased STAT3 phosphorylation (and thus STAT3 deactivation), and 
subsequently decreased cell survival and proliferation {42}.  
TNFα is often a signal for a cell to go through apoptotic-controlled death through 
induced NF-κB activation. Yet, glioblastoma are often resistant to TNFα-induced 
apoptosis{43}. It was shown that administration of CK2 inhibitors, or CK2 siRNA, in 
glioblastoma cells increased TNFα-induced apoptosis by allowing TNFα activation of the 
NF-κB pathway. Inhibition of CK2 also increased the tumor suppressor p53 activity 
through downregulation of SIRT1, which is overexpressed in glioblastoma. SIRT1 
expression decreases p53 transcription and can rescue CK2 inhibitor-induced apoptosis. 
Therefore, CK2 could be a potential target for the treatment of CNS tumors.  
Table 3. – Relative Differences in CK2 mRNA expression in brain and CNS cancer. 
Different subtypes of brain and CNS cancer are analyzed and p-values, fold changes, and 
datasets are included {39, 44-47}.  
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Astrocytoma 
CK2α 0.001 1.352 8% Shai Brain 42  
CK2β 3.12 10-14 1.518 5% Shai Brain 42  
Glioblastoma 
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CK2α 2.02 10-6 1.370 15% Sun Brain 180  
 2.33 10-4 1.294 11% Shai Brain 42  
 9.21 10-4 4.072 13% Bredel Brain 2 54  
CK2α’ 2.59 10-4 -2.132 23% Lee Brain 101  
 8.13 10-4 -1.314 17% Bredel Brain 2 54  
CK2β 1.52 10-7 1.440 2% Shai Brain  42  
  1.19 10-5 -2.338 14% Lee Brain 101  
Anaplastic Oligodendroglioma 
CK2α’ 1.15 10-6 1.637 3% French Brain 33  
CK2β 0.001 1.499 15% French Brain 33  
Anaplastic Oligoastrocytoma (oligodendroglioma + astrocytoma) 
CK2α 0.008 1.686 12% French Brain 33  
CK2α’ 0.004 -1.624 14% Bredel Brain 2 54  
CK2β 0.003 1.569 8% French Brain 33  
Cervical cancer 
Cervical cancer is the 2nd leading cause of death among women worldwide, and 
most commonly caused by the human papillomavirus (HPV). Despite well-established 
screening tests in place, and preventative measures for HPV, about half of patients are 
diagnosed at the localized stage. Standard treatments involve surgery, radiation therapy, 
and chemotherapy. 
CK2 in Cervical Cancer 
 Oncomine analysis revealed significant overexpression of all three CK2 genes in 
cervical cancer. There were no significant results for CK2αP (Table 4). CK2 activity is 
upregulated in HPV-immortalized cell lines {48}. Specifically CK2 activity is seen to 
increase during the mid to late G1 phase of the cell cycle. This proposes that CK2 may 
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stimulate HPV linked cervical cancer through promoting S-phase entry of the cell cycle 
{49}. One of the key proteins that may be an involved in this process is the E7 protein, 
encoded by the type 16 HPV. This protein acts as a transcription factor and has the 
potential to induced cellular proliferation by promoting S-phase entry. The activity of the 
viral E7 protein is in fact not intrinsic, but rather must be activated via phosphorylation. 
Indeed, CK2 may be responsible for this phosphorylation {48}. Therefore it can be 
theorized that if CK2 is upregulated in cervical tissue and exposed to HPV then cervical 
cancers are more likely to occur as compared to cervical tissue without over expression of 
CK2.  Indeed, this is the case as cell transformation are lower in low-risk HPV tumor 
types as compared to high-risk HPV types {48}. Thus, CK2 can enhance the oncogenic 
functions of HPV and subsequent development of neoplasia, and could be a potential 
therapeutic target in cervical cancer. 
One study on mouse xerographs models showed the efficacy of CK2 inhibition for 
cervical tumors. CIGB-300, a synthetic peptide that inhibits phosphor-acceptor residue 
for CK2 diminished tumor growth even after cessation {50,51}. In fact the first human 
clinical trial of a CK2 inhibitor in cervical cancers demonstrated the potential clinical 
benefit {52}. In this study, thirty-one women with cervical cancer were administered 
CIGB-300, intralesionally at four increasing doses over five consecutive days. 75% of 
patients had significant lesion reduction, 19% of patients had full histological regression 
and 48% of patients who were previously HPV DNA-positive were negative at the end of 
the trial{50,51}. At the one-year follow up, there were no recurrences or adverse events. 
Interestingly, four patients conceived, of which two were infertile prior to the 
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intervention. This study indicates that CK2 inhibition is tolerable in humans and is a 
promising treatment for cancers where CK2 is overexpressed. 
Table 4. – Relative Differences in CK2 mRNA expression in cervical cancer. 
Different subtypes of cervical cancer are analyzed and p-values, fold changes, and 
datasets are included{53}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Cervical Cancer 
CK2α 7.37 10-5 1.539 19% Pyeon Multi-cancer 84  
CK2α’ 8.59 10-7 1.914 9% Pyeon Multi-cancer 84  
CK2β 3.98 10-4 1.766 25% Pyeon Multi-cancer 84  
Esophageal cancer 
The two most common types of esophageal cancer include adenocarcinoma and 
squamous cell carcinoma. Esophageal cancer is associated with increasing age, alcohol, 
and tobacco use, and affects more men than women across all racial and ethnic groups. 
Barrett’s esophagus is a condition in which esophageal tissue turns into tissue more 
consistent to that of the intestinal lining, and often occurs in individuals with gastro-
esophageal reflux disease. This condition increases the risk for tumor genesis in 
esophageal tissues. Procedures to detect or diagnose esophageal cancer include physical 
examinations, x rays, and functional tests. Treatment options include electrocoagulation, 
surgery, radiation, chemotherapy, chemoradiation, and laser therapy. 
CK2 in Esophageal Cancer 
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 Interestingly, oncomine analysis of esophageal cancer showed significant 
downregulation of all three CK2 genes in Barrett’s esophagus and esophageal 
adenocarcinoma (Table 5). Barrett’s esophagus also showed decreased expression of 
CK2αP. In esophageal adenocarcinoma, there was conflicting data for CK2α’, with the 
Hao et al. study showing an upregulation while the Kim et al. study showed a 
downregulation. The Hao et al. study had fewer samples than the Kim study (four 
samples vs. seventy five samples) {54,55}. Therefore the Kim et al. study may 
presumptively be more representative of the overall population. Furthermore, the Kim et 
al. study utilized samples from patients prior to treatment, while the Hao et al. study did 
not explicitly state if the samples were from patients prior to or after treatment. 
 Because CK2 expression seems to be lower in esophageal cancers, CK2 may have 
lesser roles in promoting tumor growth in esophageal tissue. Intriguingly though CK2 has 
been seen to be involved in esophageal cancer invasion. Nuclear receptor corepressor 
(NCoR) is a well-known repressor of nuclear receptors and translation complexes. NCoR 
has shown the ability to represses transcription of Interferon-γ-inducible protein 10 (IP-
10), a protein with has anti-tumoral activity by inhibition of proliferation and metastasis 
{56}. CK2 has been shown to stabilize this repressing factor, thus repressing the 
transcription of IP-10.  In fact, inhibition of CK2 with 4,5,6,7-tetrabromobenzimidazole 
(TBB) led to a dose and time-dependent decrease in NCoR, increase IP-10 expression, 
and subsequent decrease in invasion of esophageal cancer cells. Similar results were 
obtained when NCoR was inhibited with NCoR-siRNAs{58}. Therefore although gene 
	  16 
deregulation was not found in esophageal tissue samples, it is still possible that CK2 gene 
upregulation is found in invasive esophageal cancer.  
 In a more recent paper, it was demonstrated that CK2 had the ability to lead to 
switches in cadherin type resulting in increased survival. It was shown that CK2 activity 
induced E-cadherin to change to N-cadherin in esophageal tissue. These N-cadherins 
resulted in resistance anoikis, a type of induced programmed cell death in which the cell 
detaches itself from the surrounding extracellular matric {59}.   
Table 5- Relative Differences in CK2 mRNA expression in esophageal cancer. 
Different subtypes of esophageal cancer are analyzed and p-values, fold changes, and 
datasets are included{54, 55 60, 61}.  
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Barrett’s Esophagus 
CK2α 5.27 10-10 -2.356 6% Kim Esophagus 118  
CK2α’ 1.36 10-4 -1.660 23% Kim Esophagus 118  
CK2αP 5.63 10-10 -1.578 6% Kim Esophagus 118  
CK2β 2.53 10-6 -1.935 15% Kim Esophagus 118  
2.65 10-7 -1.333 2% Wang 
Esophagus 
52  
Esophageal Adenocarcinoma 
CK2α 2.86 10-9 -1.805 12% Kim Esophagus 118  
0.012 -1.334 15% Kimchi 
Esophagus 
24  
CK2α’ 1.37 10-6 -1.591 19% Kim Esophagus 118  
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 3.35 10-4 2.524 7% Hao Esophagus 48  
CK2β 4.90 10-9 -2.042 13% Kim Esophagus 118  
Gastric cancer 
The most common type of gastric cancer is gastric adenocarcinoma, accounting 
for almost all manifestations gastric cancers. This carcinoma develops from the cells 
forming the mucosal layer of the stomach. Lesser common types of gastric cancer include 
carcinoid tumor and gastrointestinal stromal tumor. Gastric cancer is more common in 
men than women, and Caucasians have the lowest rate of gastric cancer development 
relative to all other racial and ethnic groups in the USA. A number of factors increase 
gastric cancer risk, including gastric Helicobacter pylori (H. pylori) infection, smoking, 
genetic predisposition, high-salt or smoked foods diet, and low intake of fruits and 
vegetables. There are two pathological variants of gastric adenocarcinoma:  intestinal and 
diffuse. Treatments include surgery, chemotherapy, radiation therapy, and 
chemoradiation. 
CK2 in Gastric Cancer 
 The oncomine data revealed overexpression of CK2α in all subtypes of gastric 
cancer in this study (Table 6). Additionally, gastric intestinal type adenocarcinoma 
showed an overexpression of the CK2αP and CK2β. CK2α’ showed a downregulation in 
diffuse gastric adenocarcinoma. However, there were conflicting findings for gastric 
intestinal type adenocarcinoma with the Cho et al. study showing decreased expression 
and the DErrico et al. study showing overexpression of CK2α’ {62,63}. It is possible that 
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different methodologies may explain the discrepancy in the results (fresh frozen vs. flash 
frozen respectively). 
One mechanism in which CK2α has shown to cause gastric cancers has been 
postulated to work through the protein deleted in breast cancer 1 (DBC1). DBC1 is 
phosphorylated and activated by CK2. The mechanism by which activated DBC1 causes 
tumorigenesis is puzzling because DBC1 was once thought to be a tumor suppressor. But 
it was shown that DBC1 inactivation actually, via inhibition of CK2 phosphorylation, led 
to decreased epithelial-to-mesenchymal transition, a hallmark for cancer formation {64}. 
As stated earlier many gastric cancers are associated with H. pylori infection. CK2 has 
also shown to be involved with these H. pylori-associated cancers. It was shown that 
infection of gastric tissue with H. pylori increases CK2 activity via the bacterial 
oncoprotein CagA {65}. It was demonstrated that this activated CK2 protein 
subsequently led to the phosphorylation of α-catenin, disrupting α-catenin/β-catenin 
complexes. This disruption helped lead the gastric tissue to undergo epithelial-to-
mesenchymal transition in two ways. First, disruption of the α-/β-catenin complexes led 
to destabilization of the E-cadherins they were bound to, leading to decreased integrity of 
adherence junctions of gastric tissue. Secondly, once the α-/β-catenin complexes would 
disassociate, the β-catenin would translocate to the nucleus and lead to increase 
transcription of MMP7{65}. MMP7 is a protein that is excreted from the cell and can 
break down the extracellular matrix. Therefore H. pylori could, though CK2,  increase 
cell proliferation and enhance the metastatic ability of gastric cells.         
CK2 and Patient survival of Gastric Cancer 
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Kaplan-Meier plotter analysis showed that higher expression of CK2α (p = 0.010) 
and CK2β (p = 1.6 10-5) directly correlated with lower survival in gastric cancer (Table 
7). Our findings are consistent with previously published results showing that CK2α 
protein is overexpressed in gastric carcinoma correlating with poor survival {64}. Indeed, 
CK2α was found to be an independent prognostic indicator for gastric cancer as nuclear 
levels of CK2α were associated with higher tumor stage, presence of lymph node 
metastasis and even presence of venous invasion. Furthermore, elevated levels of nuclear 
CK2β correlated with depth of invasion and with poor survival in gastric cancer {66}. 
Therefore, nuclear CK2β levels could be an independent prognostic marker for gastric 
carcinoma. This data shows that increased CK2α and CK2β levels can be correlated with 
invasive potential of gastric cancer cells. 
Table 6. – Relative Differences in CK2 mRNA expression in gastric cancer. Different 
subtypes of gastric cancer are analyzed and p-values, fold changes, and datasets are 
included {62, 63, 67}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Gastric Intestinal Type Adenocarcinoma 
CK2α 1.98 10-10 1.611 5% Chen Gastric 132  
7.64 10-8 1.661 8% DErrico Gastric 69  
CK2α’ 4.75 10-4 -1.454 5% Cho Gastric 90  
 5.68 10-5 1.473 20% DErrico Gastric 69  
CK2αP 1.34 10-5 1.346 16% Chen Gastric 132  
CK2β 4.56 10-7 1.761 11% DErrico Gastric 69  
Diffuse Gastric Adenocarcinoma 
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CK2α 6.90 10-5 1.540 5% Chen Gastric 132  
CK2α’ 2.95 10-4 -1.549 6% Cho Gastric 90  
 
Table 7. – Overall patient survival as an effect of high gene expression levels in 
gastric cancer. 
High levels of Expression:  Survival p-value 
CK2α Lower survival 0.01 
CK2β Lower survival 1.6 10-5 
 
Head and neck cancer 
Head and neck cancers are a group of cancers that can affect the oral cavity, 
pharynx, larynx, paranasal sinuses and nasal cavity, salivary glands, nose and throat. 
Almost all head and neck cancers originate from squamous cells. There is a diverse range 
head and neck cancers, including, but not limited to, tonsillar carcinoma, tongue 
carcinoma, floor of the mouth carcinoma, and oropharyngeal carcinoma. The two highest 
risk factors for head and neck cancer are alcohol and tobacco use. Other risk factors 
include HPV infection (especially HPV-16), Esptein-Barr virus infection, chewing of 
paan (common among Southeast Asians), high consumption of mate or salty foods, poor 
oral hygiene, exposure to radiation, and industrial exposures. Treatment options for 
individuals with head and neck cancer include surgery, chemotherapy, targeted therapy, 
and/or radiation therapy. 
CK2 in Head and Neck Cancer  
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 Oncomine analysis revealed that CK2α transcript was overexpressed in floor of 
the mouth carcinoma, oropharyngeal carcinoma, and tongue carcinoma (Table 8). CK2β 
transcript was overexpressed in floor of the mouth carcinoma, tongue carcinoma, and 
tonsillar carcinoma. Only tongue carcinoma had significant results for CK2α’, showing 
an overexpression. There were no significant results for CK2αP. In line with our findings, 
a published study found overexpression of all three CK2 transcripts in head and neck 
squamous cell carcinoma {68}. Another study also found increased protein expression 
for all three CK2 genes in head and neck squamous cell carcinoma {69}. Two published 
studies further support our findings, where they found an association between high levels 
of CK2 activity, both nuclear and cytosolic, and head and neck cancer and this increased 
activity is correlated with patient survival {70-71}. 
 One protein that has linked to head and neck squamous cell carcinoma and is 
correlated with patient survival is IL-6, a cytokine {72}. Interestingly, a recent study 
demonstrated that IL-6, in fact, activates CK2α. In head and neck cancer IL-6’s activation 
of CK2α results in the phosphorylation and stabilization of a transcription factor, Twist. 
Twist has been shown to be upregulated in head and neck cancer. Moreover Twist is 
known to be important for amplifying cell motility leading to increasing metastatic ability 
and understandably is correlated with patient survival. {73-75}.  
 CK2α can also increase head and neck cancers via aberrant activation of NF-κB. 
It has been shown that NF-κB overexpression in head and neck cancer contributes to cell 
survival, while inhibition of NF-κB results in apoptosis {76-78}. The mechanism by 
which CK2α activates NF-κB was postulated to be through the phosphorylation and 
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activation of Inhibitor KappaB Kinase (IKK) {79}. IKK, whose activity is dependent on 
CK2, activates NF-κB and inhibits an endongeous NF-κB repressor. Furthermore, CK2β 
has been linked to having a role in of NF-κB activation. Suppression of CK2β with 
siRNA led to decrease in activation of NF-κB, suggesting the important of the tetrameric 
complex and the regulatory role of CK2β in head and neck cancer {69}. In fact, 
knockdown of CK2 in head and neck cancer lead to multiple anti-cancerous effects. 
Other than the decrease in NF-κB activation, there was also a decrease in the 
transcription of BCL-XL and CCND1 each of which increase cell survival and cell cycle 
progression respectively. Furthermore, CK2 inhibition lead also to increase in p53 and 
Tap63 levels, each of which involved in growth arrest and apoptosis {69}. Similarly, 
administration of CK2 inhibitors in head and neck squamous cell carcinoma cell lines led 
to decreased cell growth, inhibition of cell cycling, and increased apoptosis {68}.  
Table 8. – Relative Differences in CK2 mRNA expression in head and neck cancer. 
Different subtypes of head and neck cancer are analyzed and p-values, fold changes, and 
datasets are included {53,80,81}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Sample
s 
 
Floor of the Mouth Carcinoma 
CK2α 1.69 10-4 2.313 7% Pyeon Multi-cancer 84  
CK2β 1.44 10-4 1.923 6% Pyeon Multi-cancer 84  
Oropharyngeal Carcinoma 
CK2α 6.85 10-4 1.737 7% Pyeon Multi-cancer 84  
Tongue Carcinoma 
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CK2α 1.31 10-6 1.735 2% Pyeon Multi-cancer 84  
CK2α’ 1.74 10-6 1.836 3% Pyeon Multi-cancer 84  
CK2β 5.75 10-4 1.689 14% Pyeon Multi-cancer 84  
3.76 10-4 1.409 19% Talbot Lung 93  
0.003 1.605 23% Estilo Head-Neck 58  
Tonsillar Carcinoma 
CK2β 0.006 2.704 7% Pyeon Multi-cancer 84  
Kidney cancer 
Types of kidney cancer include renal cell carcinoma (which can be sub-divided 
into clear cell, papillary, and chromophobe carcinoma), renal pelvis carcinoma, 
transitional cell carcinoma, Wilms tumor (occurs in children under 5 years of age), and 
renal sarcoma. Furthermore, a benign renal tumor is known as a renal oncocytoma. 
Factors contributing to kidney cancer include smoking, obesity, hypertension, and 
particular conditions that are inherited. There is currently no standard screening test for 
kidney cancer. For individuals with increased risk due to inherited conditions, computed 
tomography (CT) and magnetic resonance imaging (MRI) are typically utilized to screen 
for kidney cancer. Treatments include surgery, radiation, chemotherapy, biological 
therapy, and targeted therapy. 
CK2 in Kidney Cancer 
 Data from Oncomine revealed a significant overexpression of all three CK2 genes 
in renal oncocytoma and renal cell carcinoma (Table 9). Wilms tumor showed significant 
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overexpression of CK2α and CK2β, and clear cell sarcoma of the kidney showed 
overexpression of CK2α. There were no significant results for CK2αP.  
Confirming this data studies of renal clear cell carcinoma confirmed elevated 
levels of CK2α activity in renal clear cell carcinomas {82}. Additionally, another recent 
study found elevated protein expression of CK2 kinases, CK2α and CK2α’, in renal cell 
carcinoma {83}. However, in this case it was the result of elevated translation not 
transcription as CK2 protein levels were elevated rather than mRNA levels (mRNA 
levels were decreased 1.5-16 times). The authors proposed that there is post-
transcriptional dysregulation. The study went on to show that CK2α also regulates the 
cellular proliferation and apoptosis. By using CX-4549, a CK2α inhibitor, it was shown 
that cellular proliferation diminished and apoptosis was permitted in renal cancer cells. 
This inhibition of CK2α showed to increase ERK and p38 MAPK activation. It was also 
recently proposed that although ERK is traditionally known to increase cellular 
proliferation, it may also be an initiator of apoptosis {83}.   
Table 9. – Relative Differences in CK2 mRNA expression in kidney cancer. Different 
subtypes of kidney cancer are analyzed and p-values, fold changes, and datasets are 
included {84-86}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Chromophobe Renal Cell Carcinoma 
CK2α 1.64 10-5 2.212 1% Yusenko Renal 67  
CK2α’ 0.002 1.517 13% Jones Renal 92  
Clear Cell Renal Cell Carcinoma 
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CK2α 1.64 10-5 1.410 20% Jones Renal 92  
1.11 10-4 1.444 6% Yusenko Renal 67  
CK2β 4.79 10-8 1.506 12% Jones Renal 92  
Papillary Renal Cell Carcinoma 
CK2α 3.15 10-5 1.543 2% Yusenko Renal 67  
 5.50 10-4 1.360 26% Jones Renal 92  
Renal Wilms Tumor 
CK2α 5.36 10-5 2.199 1% Yusenko Renal 67  
 4.39 10-4 1.417 3% Cutcliffe Renal 35  
CK2β 0.002 1.500 5% Cutcliffe Renal 35  
 0.004 1.607 6% Yusenko Renal 67  
Clear Cell Sarcoma of the Kidney 
CK2α 9.50 10-5 1.569 3% Cutcliffe Renal 35  
Renal Oncocytoma 
CK2α 4.76 10-5 1.993 2% Yusenko Renal 67  
CK2α’ 1.11 10-7 1.505 7% Jones Renal 92  
 0.004 2.015 11% Yusenko Renal 67  
CK2β 0.005 1.424 12% Yusenko Renal 67  
 
Leukemia 
Leukemia is a cancer of the blood and one of the most common childhood 
cancers. . Leukemia can be divided into four main subtypes: acute myeloid leukemia 
(AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and 
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chronic myeloid leukemia (CML). There is a 5th subtype Hairy cell leukemia (HCL), 
which is the overproduction of B cells, but this form of leukemia is very rare. In these 
cancer types, the bone marrow overproduces functionally abnormal types of blood cells. 
Such cells are often non-apoptotic, and thus can crowd and impede proper functionality 
of normal white blood cells, red blood cells, and platelets. In the past decade, leukemia 
cases have risen each year. Risk factors include smoking, chemical exposure such as 
benzene, radiation exposure, history of chemotherapy or radiation therapy, inherited or 
genetic conditions, blood disorders, and a family history of leukemia. There are currently 
no implemented standard screens for blood cancers. Treatments include standard cancer 
treatment of chemo or radiation therapies, stem cell transplant, and more recently 
immune cell replacement or engineering. 
CK2 in Leukemia 
Oncomine analysis revealed overexpression of CK2β and CK2α’ in ALL, but an 
overexpression of CK2α in T-cell ALL and conflicting results in B-cell ALL (Table 10). 
In line with the findings in ALL, a previous study found an overexpression and/or 
hyperactivation of CK2α in primary T-cell ALL cells {87 }. Here it was proposed that 
CK2α suppresses PTEN activation, leading to decreased phosphorylation of PIP3 by 
PTEN. When PIP3 is phosphorylated it has the ability to inhibit P13K/Akt signaling 
cascade. Therefore, this decreased phosphorylation of PIP3 leads to more pronounced 
PI3K/Akt signaling, which is known to promote proliferation and decreases apoptosis, 
thus promoting tumor genesis. To further bolster this correlation, it was shown that 
inhibition of CK2 with TBB led to restoration of PTEN activity and decreased PI3K/Akt 
	  27 
signaling. This ultimately led to T-cell ALL cell apoptosis. Importantly, normal T-cells 
were unaffected by TBB.  
Additionally, CK2α can interact with BCR of the p190 or p210 forms of BCR-
ABL oncogene, involved in ALL and CML {88}. This interaction is important for cancer 
cells with the BCR-ABL fusion oncogene. CK2 inhibition led to a decrease in 
proliferative ability of cells overexpressing BCR-ABL both in vitro and in vivo, 
providing evidence for the importance of CK2α in ALL and CML. Together, these 
experiments demonstrate a role for CK2α in ALL and CK2 as a potential target for cancer 
therapy.   
CLL also showed overexpression of CK2α’, but a downregulation of CK2α. It has 
been demonstrated that CK2 expression and activity is larger than normal in CLL cells 
but al {89}. In fact, it was shown that CK2 inhibition led to CLL apoptosis while leaving 
normal T and B cells unaffected, suggesting that CK2 does in fact promote survival in 
CLL. It is suggested that CK2 acts in a similar manner as it does in ALL in which PTEN 
activity is hindered by CK2 {89}.  It is suggested that inhibiting CK2 may be useful in a 
clinical setting treating CLL {90}.     
In AML, oncomine analysis showed an overexpression of CK2α, CK2α’ and 
CK2αP. In accordance with our finding, a published study demonstrated CK2α 
overexpression in AML {91}. It is suggested that CK2 is involved in cell survival 
through P53 suppression and STAT3 activation (92).  
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Table 10. – Relative Differences in CK2 mRNA expression in leukemia. Different 
subtypes of leukemia are analyzed and p-values, fold changes, and datasets are included 
{93-99}.  
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Acute Myeloid Leukemia 
CK2α 0.002 1.609 27% Andersson Leukemia* 127  
CK2α’ 1.47 10-7 2.030 5% Andersson Leukemia* 127  
 1.05 10-20 1.417 5% Haferlach Leukemia 2096  
CK2αP 0.002 1.609 27% Andersson Leukemia* 127  
CK2β 3.26 10-8 2.006 4% Andersson Leukemia* 127  
 2.96 10-4 -1.928 5% Stegmaier Leukemia 87  
B-Cell Acute Lymphoblastic Leukemia 
CK2α 1.57 10-4 -1.639 5% Maia Leukemia 28  
 0.001 -1.758 10% Coustan-Smith 
Leukemia* 
288  
 0.004 1.528 35% Andersson Leukemia* 127  
CK2α’ 4.54 10-26 1.421 5% Haferlach Leukemia 2096  
 2.65 10-7 2.189 10% Andersson Leukemia* 127  
CK2β 6.45 10-15 2.130 2% Andersson Leukemia* 127  
T-Cell Acute Lymphoblastic Leukemia 
CK2α 4.04 10-4 1.743 20% Andersson Leukemia* 127  
CK2α’ 1.77 10-7 2.496 4% Andersson Leukemia* 127  
CK2β 1.44 10-8 2.654 2% Andersson Leukemia* 127  
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Pro-B Acute Lymphoblastic Leukemia 
CK2α’ 9.25 10-25 1.515 3% Haferlach Leukemia 2096  
Chronic Lymphocytic Leukemia 
CK2α 1.34 10-6 -2.228 5% Rosenwald Multi-
cancer 
102  
 5.89 10-34 -1.453 7% Haferlach Leukemia 2096  
 2.06 10-4 -1.505 10% Alizadeh Leukemia 120  
CK2α’ 3.13 10-34 1.455 8% Haferlach Leukemia 2096  
CK2β 3.33 10-4 1.885 10% Haslinger Leukemia 111  
 2.81 10-6 -1.391 8% Basso Lymphoma 336  
 0.004 -1.381 8% Rosenwald 
Lymphoma 
293  
Hairy Cell Leukemia 
CK2α’ 1.42 10-8 -1.876 3% Basso Lymphoma 336  
 Non-Hodgkin Lymphoma 
Lymphoma is cancer of certain white blood cells called lymphocytes that reside in 
the lymphatic system and is the leading blood cancer in the USA. Lymphoma can be 
subdivided into two major types: Hodgkin lymphoma and non-Hodgkin lymphoma 
(NHL). Hodgkin lymphoma is characterized by histological presence of Reed-Sternberg 
cells, which are malignant mature B cells. Significant data for Hodgkin lymphoma was 
unavailable; therefore only NHL data will be reported. NHLs are a diverse group of 
blood cancer that can be formed predominately from B-cells, less commonly in T-cells, 
and rarely in NK cells. NHLs can be further subdivided into high grade or fast-growing 
and low grade or slow-growing.  Subtypes of B-cell NHLs include high grade 
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lymphomas (diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and primary 
effusion lymphoma) and low grade lymphomas. DLBCL can be further subdivided into 
activated B cell-like DLBCL and germinal center B cell-like DLBCL. The most common 
high grade NHL is DLBCL; the most common low grade NHL is follicular lymphoma. 
T-cell NHL can include anaplastic large cell lymphoma, angioimmunoblastic T-cell 
lymphoma, and unspecified peripheral T-cell lymphoma, which are all high-grade 
lymphomas. Risk factors for lymphoma include viral infections, Helicobacter pylori 
infection, human T-cell leukemia/lymphoma virus infection, or having a compromised 
immune system. Treatment regimens differ between high and low grade NHL. Generally 
patients with high grade NHL are treated with an intensive course of chemotherapy. 
Patients with localized low grade NHL are treated with radiotherapy, which is effective in 
controlling and even potentially curing the lymphoma. Other treatment options include 
targeted therapy and/or stem cell transplant. 
CK2 in Non-Hodgkin Lymphoma 
 Oncomine analysis revealed downregulation of all three CK2 transcripts in low 
grade B-cell NHL (Table 11). Conversely in high grade B-cell and T-cell NHL, all three 
CK2 transcripts are upregulated. There were no significant results for CK2αP. In line 
with our findings, a recently published study demonstrated high expression of all three 
CK2 genes in Burkitt’s lymphoma and DLBCL, and this correlated with increased CK2α 
and CK2β protein levels {100}. In contrast, but in line with our findings, it was shown 
that follicular lymphoma had lower expression of all CK2 genes. Pharmacological 
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inhibition of CK2 activity with CX-4945 led to dose-dependent decreased cell survival in 
both Bukitt’s lymphoma and DLBCL, indicating a role for CK2 in high grade lymphoma.  
Table 11. – Relative Differences in CK2 mRNA expression in non-Hodgkin 
lymphoma. Different subtypes of lymphoma are analyzed and p-values, fold changes, 
and datasets are included {101-107}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Burkitt’s Lymphoma 
CK2β 2.44 10-4 2.331 9% Brune Lymphoma 67  
Activated B-Cell-like Diffuse Large B Cell Lymphoma 
CK2β 1.18 10-4 1.616 12% Alizadeh Lymphoma 120  
Follicular Lymphoma 
CK2α 3.21 10-7 -1.421 17% Compagno 
Lymphoma 
136  
CK2α’ 8.51 10-4 -2.263 3% Storz Lymphoma 27  
CK2β 4.37 10-8 -1.493 13% Compagno 
Lymphoma 
136  
Anaplastic Large Cell Lymphoma 
CK2α 2.78 10-6 1.844 5% Piccaluga 
Lymphoma 
60  
0.010 1.437 25% Eckerle Lymphoma 64  
CK2α’ 3.66 10-8 2.195 2% Piccaluga 
Lymphoma 
60  
CK2β 0.003 2.002 25% Piccaluga 
Lymphoma 
60  
Angioimmunoblastic T-Cell Lymphoma 
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CK2α 4.57 10-4 1.940 15% Piccaluga 
Lymphoma 
60  
CK2α’ 0.004 1.858 25% Piccaluga 
Lymphoma 
60  
CK2β 0.006 1.549 26% Piccaluga 
Lymphoma 
60  
Unspecified Peripheral T-Cell Lymphoma 
CK2α 3.32 10-5 1.525 21% Piccaluga 
Lymphoma 
60  
Primary Effusion Lymphoma 
CK2α’ 0.001 -1.853 11% Basso Lymphoma 336  
Myeloma 
Myeloma is the third most common blood cancer. Myeloma is caused by 
abnormal plasma cells that accumulate in bone marrow and can cause damage to the 
surrounding bone and throughout the body. Buildup of myeloma cells in several bones 
leads to the condition “multiple myeloma”. Other than bone damaged, myeloma can also 
cause a significantly weaken immune system, kidney failure, and neurological systems. 
All of which are associated with the overproduction of antibodies by these cancerous 
plasma cells. Subtypes of myeloma include smoldering myeloma, symptomatic myeloma, 
and plasma cell leukemia. The buildup of antibodies produced by myeloma cells in 
blood, urine, and organs leads to a condition called monoclonal gammopathy of 
undetermined significance (MGUS). While this condition can be asymptomatic, it can 
become associated with other diseases or progress to myeloma. There is currently no 
standard screening test for myeloma. Myeloma treatments include chemotherapy, 
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targeted therapy, biological therapy, treatment with corticosteroids, stem cell transplant 
with high-dose chemotherapy, surgery, or watchful waiting. 
CK2 in Myeloma 
 Oncomine analysis revealed significant overexpression of CK2α and CK2β in 
both smoldering myeloma and plasma cell leukemia (Table 12). MGUS showed opposing 
data for CK2α in which one study stating an underexpression of the transcript and another 
study showing an overexpression of CK2α transcipts {108-109}. This could be the result 
of differing sample sizes, in which the study that postulated underexpression had 11 
samples, and the study postulating overexpression having 44 samples.  
Similar to the data extracted, a published study also observed an increased CK2α 
protein level and activity in patients with myeloma {110}. Similar to other cancer types it 
was shown that CK2 inhibition led to apoptosis of myeloma cells, indicating a role for 
CK2 in cell survival in myeloma {112, 113}. Additionally it was also demonstrated that 
myeloma cells were more responsive to melphalan, a chemotherapeutic, when CK2 was 
inhibited. This allows one to postulate that CK2 inhibition, in conjunction with traditional 
chemotherapeutics, can be a more effective method for the treatment cancers, specifically 
myeloma. 
The endoplasmic reticulum stress/unfolded protein response (UPR) is mechanism 
that allows a cell to go into an apoptotic state when too much protein is being produced. 
This stress response would be specifically important in a myeloma cell that is producing 
abnormally large amounts of protein antibodies. CK2 is been shown to be involved in the 
endoplasmic reticulum stress/unfolded protein response of myeloma cells {113}. HSP90 
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is a chaperone that, when active, has been shown to reduce the UPR. It was demonstrated 
that CK2 has the ability to phosphorylate CDC37, a co-chaperone, which subsequently 
stabilizes a HSP90 complex and ultimately decreasing the UPR. Inhibition of CK2 led to 
reduction of ER stress sensors and increase in ER-stress induced apoptosis, indicating the 
role of CK2 in preventing apoptosis in the presence of accumulated misfolded or 
unfolded proteins. Inhibition of both CK2 and HSP90 led to a synergistic anti-
tumorigenic effect, as compared to separate inhibition of each. 
Table 12. – Relative Differences in CK2 mRNA expression in myeloma. Different 
subtypes of myeloma are analyzed and p-values, fold changes, and datasets are included 
{108-109}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Monoclonal Gammopathy of Undetermined Significance 
CK2α 6.61 10-5 -1.619 1% Agnelli Myeloma 3 158  
1.18 10-6 1.594 4% Zhan Myeloma 3 78  
Smoldering Myeloma 
CK2α 3.36 10-9 1.763 1% Zhan Myeloma 3 78  
CK2β 1.73 10-4 1.779 22% Zhan Myeloma 3 78  
Plasma Cell Leukemia 
CK2α 0.001 1.881 8% Agnelli Myeloma 3 158  
CK2β 6.40 10-4 1.461 7% Agnelli Myeloma 3 158  
Liver cancer 
Liver cancer most commonly begins in hepatocytes giving rise to hepatocellular 
carcinoma. Other liver cancer subtypes include fibrolamellar carcinoma, 
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hemangiosarcoma, and hepatoblastoma, but are much more rare. Hepatocellular 
carcinoma is most commonly caused by cirrhosis of the liver due to alcohol abuse. Other 
risk factors include hepatitis, hemochromatosis, obesity, and diabetes. There is currently 
no standard screening test for liver cancer. Treatments include surgery, liver transplant, 
ablation, emolization, radiation therapy, chemotherapy, and targeted therapy. 
CK2 in Liver Cancer 
 Oncomine analysis showed significant overexpression of CK2α and CK2β in 
hepatocellular carcinoma (Table 13). There were no significant results for CK2α’ and 
CK2αP. Supporting the data extracted a recent study revealed high levels of CK2α 
protein in hepatocellular carcinoma {114}. In fact, chemical inhibition of CK2 led to 
decreased proliferation and survival of hepatocellular carcinoma cells {115}. Another 
study showed that knockdown of CK2α in hepatocellular carcinoma cells inhibits 
migration and invasion {116 Additionally Hh signaling, which is involved in metastasis, 
was also inactivated as a result. It was also shown that CK2 played a role in the up-
regulation of histone deacetylase, an important transcriptional modulator that can is 
prominent in liver cancer{114}.  
When a cell is needed to induce apoptosis one means by which this can be achieved is 
through the expression of a Fas receptor. This Fas receptor can then bind to a Fas ligand 
that is expressed on a T cell, which can subsequently kill the Fas receptor expressing cell. 
It has been shown that CK2 has also been found to decrease sensitivity to Fas ligand 
therefore decreases episodes of apoptosis when needed, protecting cancer cells from cell 
death. Furthermore, in hepatocellular carcinoma cells CK2 inhibition led to dose-
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dependent increase in cell apoptosis due to increased sensitivity to death ligand-induced 
apoptosis {117, 118}. Similar inhibition of CK2 also showed increased apoptotic event 
induced by natural killer (NK) cells, suggesting that CK2 also weakens signals to NK 
cells in cancer.  
Table 13. – Relative Differences in CK2 mRNA expression in liver cancer. Different 
subtypes of liver cancer are analyzed and p-values, fold changes, and datasets are 
included {119-120}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Hepatocellular Carcinoma 
CK2α 9.93 10-45 1.801 6% Roessler Liver 2 445  
1.94 10-5 1.774 9% Roessler Liver 43  
CK2β 1.69 10-50 1.630 4% Roessler Liver 2 445  
 1.53 10-6 1.720 6% Roessler Liver 43  
 1.07 10-8 1.417 8% Chen Liver 197  
Skin cancer 
Skin cancers include melanoma and non-melanoma skin cancer. Non-melanoma 
skin cancer can be further subtyped into basal cell carcinoma and squamous cell 
carcinoma. Melanoma is the most fatal form of skin cancer. It arises from malignant 
melanocytes, and is most commonly caused by DNA damage due to ultraviolet light 
exposure. On the other hand, non-melanoma skin cancer usually responds well to 
treatment and is rarely metastatic. A risk factor for skin cancer is the presence of benign 
melanocytic skin nervus, more commonly known as moles and freckles. Other risk 
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factors include fair skin, high exposure to natural or artificial UV light, history of 
blistering sunburns, and history of melanoma or atypical moles. Current standard screens 
for melanoma include visual examination. Treatments include surgery, chemotherapy, 
targeted therapy, biological therapy, and radiation therapy.  
CK2 in Melanoma 
 Oncomine analysis revealed significant overexpression of all three CK2 genes in 
benign melanocytic skin nervus (Table 14). Non-melanoma skin cancer subtypes showed 
overexpression of CK2α, and overexpression of CK2α’ in squamous cell carcinoma (no 
significant results for basal cell carcinoma). Melanoma showed overexpression of CK2α 
and CK2β, and underexpression of CK2α’. There were no significant results for CK2αP.  
 The response to UV exposure is an important process in preventing melanoma 
development. Two important proteins involved in mediating this response include NF-κB 
and p53, which as discussed before are regulated by CK2. It was shown in melanoma 
cells if CK2 was inhibited then not only did NF-κB ability to bind to DNA decreased but 
also that the levels of surviving, a anti-apoptotic protein, decreased and apoptosis events 
increased {121}  
Table 14. – Relative Differences in CK2 mRNA expression in skin cancer. Different 
subtypes of melanoma are analyzed and p-values, fold changes, and datasets are included 
{122-124}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Benign Melanocytic Skin Nervus (moles and freckles) 
CK2α 0.002 5.016 10% Talantov Melanoma 70  
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CK2α’ 0.004 1.566 13% Talantov Melanoma 70  
CK2β 8.28 10-4 1.797 8% Talantov Melanoma 70  
 1.02 10-5 1.754 2% Haqq Melanoma 37  
Skin Basal Cell Carcinoma 
CK2α 5.15 10-4 1.453 6% Riker Melanoma 87  
Skin Squamous Cell Carcinoma 
CK2α 1.02 10-7 2.081 1% Riker Melanoma 87  
CK2α’ 0.015 1.590 23% Riker Melanoma 87  
Melanoma 
CK2α 9.11 10-4 7.026 17% Talantov Melanoma 70  
CK2α’ 1.91 10-4 -2.533 3% Riker Melanoma 87  
CK2β 9.30 10-5 2.478 10% Talantov Melanoma 70  
 0.004 2.198 14% Haqq Melanoma 37  
Mesothelioma 
Mesothelioma is a rare type of cancer that forms from cells of the mesothelium. 
Mesothelioma can be subdivided based on location of origin and includes pleural, 
peritoneal, pericardial and testicular . Mesothelioma can also be classified according to 
their cell type, epithelial , sarcomatoid, and biphasic epithelial and sarcomatoid). Patients 
with epithelial mesothelioma have the highest survival rate due to better response to 
treatment. A well-known risk factor include exposure to asbestos, even if exposure is 
limited. Other risk factors include radiation exposure, intrapleural thorium dioxide, 
inhalation of other fibrous silicates, or inheriting a germline mutation on the BAP1 gene. 
There is no standard screening test for mesothelioma, especially for those who were 
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exposed to asbestos. Treatment options include surgery, radiation therapy, chemotherapy, 
immunotherapy, and/or intraoperative intraperitoneal chemotherapy. 
CK2 in Mesothelioma 
Oncomine analysis showed significant overexpression of CK2α and CK2β 
transcripts in malignant pleural mesothelioma (Table 15). There were no significant 
results for CK2α’ and CK2αP. These findings were consistent with a recently published 
study, where they also found an overexpression of CK2α mRNA and protein levels in 
malignant pleural mesothelioma {125}. In this model, CK2α was found to be a positive 
regulator of Hh/Gli1 signaling which is involved in maintenance of stem cells. 
Furthermore, pharmacological inhibition of CK2 with CX-4945 led to a dose-dependent 
downregulation of Gli1 activity. 
Table 15. – Relative Differences in CK2 mRNA expression in mesothelioma. 
Different subtypes of mesothelioma are analyzed and p-values, fold changes, and datasets 
are included {126}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Malignant Pleural Mesothelioma 
CK2α 2.76 10-6 2.194 2% Gordon Mesothelioma 54  
CK2β 7.96 10-7 1.485 2% Gordon Mesothelioma 54  
Testicular cancer 
Almost all forms of testicular cancer are derived from germ cells, and more rare 
forms being derived from the supporting Leydig cells and Sertoli cells. Germ cell-related 
testicular cancer can be subdivided into seminomas and non-seminomas. Non-seminoma 
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testicular cancer can be further subdivided into teratomas, embryonal carcinomas, mixed 
germ cell tumors, and yolk sac tumors. There are many risk factors for testicular cancer, 
including cryptorchidism, Turner syndrome, androgen insensitivity syndrome, 
Klinefelter’s syndrome, low fertility, and family history. Treatment options for testicular 
cancer include surgery, radiation therapy, and chemotherapy. 
CK2 in Testicular Cancer 
 Counter to most other cancer types, oncomine analysis revealed significant 
downregulation of all three CK2 genes and CK2αP in both seminomatous and non-
seminomatous testicular cancer (Table 16). It is also shown that CK2 activity is highest in 
normal testicular tissue in comparison to other tissues{127}. Therefore it can be assumed 
that CK2 activity is imperative to normal testicular function. CK2α’ is required for male 
gametogenesis. Knockout of CK2α’ in mice leads to oligospermia and globozoospermia, 
which is defined as spermatozoa having round heads {127}. Additionally, such male 
mice are infertile due to germ cell chromatin breakdown, a risk factor for testicular 
cancer {132}. Decreased expression of CK2β in testicular cancer could indicate a loss of 
regulation over the CK2 kinases. Therefore, dysregulation of the three CK2 genes in 
testicular cancer, particularly CK2α’ and CK2β, could signify a dysfunction in the normal 
signaling pathway for gametogenesis, and possibly a shunting toward another pathway 
leading to tumor formation. 
This could be in part due to a loss of CK2 Target protein 2 (CKT2) 
phosphorylation, a target of CK2 found in testis. CK2, specifically CK2α’, 
phosphorylates and activates CKT2, which is responsible for chromatin condensation in 
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spermatids. One means in which CK2 can lead to malignant development gonadal tissue 
is through the TSPY protein. TSPY is a protein that has various important functions in 
testicular tissues including chromatin remodeling and gene expression. It was shown 
when the phosphorylation site of CK2 on TSPY is mutated, TSPY is prevented from 
entering the nucleus and subsequently is inhibited from regulating genes. This may be a 
possible means by which downregulation of CK2 leads to testicular cancer {128}. As 
Korkola et al. showed that there is sets of stem cell genes that when down regulated can 
promote male germ line cancers{129}. It may be that down regulation of CK2 can lead to 
underexpression of certain stem cell genes and subsequently leads to testicular cancer.   
Table 16. – Relative Differences in CK2 mRNA expression in testicular cancer. 
Different subtypes of germ cell tumor are analyzed and p-values, fold changes, and 
datasets are included {129-131}. 
Gene P-Value Fold Change Rank (Top %) Dataset #Samples  
Testicular Seminoma 
CK2α 0.003 -1.645 22% Sperger Others 74  
CK2αP 0.003 -1.645 22% Sperger Others 74  
Seminoma, NOS 
CK2α 1.21 10-5 -2.224 13% Korkola Seminoma 107  
CK2α’ 8.56 10-11 -8.257 1% Korkola Seminoma 107  
CK2β 2.11 10-6 -2.180 10% Korkola Seminoma 107  
Testicular Teratoma 
CK2α 0.03 -1.531 16% Skotheim Testis 30  
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CK2α’ 0.006 -4.093 7% Skotheim Testis 30  
CK2β 0.009 -2.471 9% Skotheim Testis 30  
Teratoma, NOS 
CK2α 3.56 10-9 -3.805 4% Korkola Seminoma 107  
CK2α’ 5.12 10-12 -9.860 1% Korkola Seminoma 107  
CK2β 3.93 10-8 -2.791 6% Korkola Seminoma 107  
Embryonal Carcinoma, NOS 
CK2α 5.98 10-8 -2.666 6% Korkola Seminoma 107  
CK2α’ 6.42 10-12 -9.596 1% Korkola Seminoma 107  
CK2β 1.59 10-6 -2.349 11% Korkola Seminoma 107  
Mixed Germ Cell Tumor, NOS 
CK2α 1.25 10-7 -2.302 10% Korkola Seminoma 107  
CK2α’ 4.33 10-12 -7.593 3% Korkola Seminoma 107  
CK2β 6.47 10-7 -2.377 12% Korkola Seminoma 107  
Yolk Sac Tumor, NOS 
CK2α’ 1.21 10-9 -6.599 1% Korkola Seminoma 107  
CK2β 9.08 10-5 -2.123 15% Korkola Seminoma 107  
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CONCLUSION 	  
Cancer is one of the leading causes of death in United States of America and 
worldwide and continues to be a greatly perplexing biomedical and public health 
problem. Over the past few decades, the abilities to screen for, diagnoses, and treat cancer 
has improve substantially in most cancer types. One among many reasons for this 
improvement is the discovery and clinical use for biochemical markers for diagnosing 
different cancer types and the possible aggressiveness of certain cancers.  For example 
BRCA1 is used as a cancer biomarker for breast cancer, and AFP is a cancer biomarker 
for liver cancer and each marker tells a physician a certain amount of information about 
the cancer and can influence more effected treatment choices. Here we postulate that 
CK2 can be a potential diagnostic marker for cancer and perhaps can be effective as a 
target for cancer treatment.  
As demonstrated in so many cancer types, CK2 has shown itself as not only a 
protein needed for normal cellular function but also as a possible oncoprotein.  It was 
demonstrated that in most cancers CK2 transcripts were upregulated, though there were 
certain cancer types in which CK2 was downregulation (Table 17). For example, all three 
CK2 genes and CK2αP were downregulated in testicular cancer, a cancer not widely 
studied on with regards to CK2. Here we postulate that aberrant expression of CK2 in 
testicular cancer, importantly CK2α’ and CK2β, may lead to a dysfunction in 
gametogenesis leading to infertility, which poses a substantial increased risk of 
developing testicular cancer {132}.  
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We also postulate that the pervasiveness of a certain cancer type can be 
determined by CK2 levels. For example, in high grade NHL, oncomine data showed 
overexpression of all three CK2 transcripts whereas they were downregulated in CK2 
transcripts showed low grade NHL. These findings are supported by recent literature 
{100}. This may indicate that as NHL progresses from low to high grade, there is a 
switch in the overall transcript expression of CK2 and that CK2 could contribute the 
aggressiveness of the lymphoma. It may be possible that future data in other cancers will 
also show a correlation between aggressive and CK2 level.  
 Kaplan-Meier plotter analysis on gastric cancer has shown direct correlations 
between CK2 transcript dysregulation and overall patient survival. Here, higher levels of 
CK2α and CK2β gene expression led to lower survival. These are in line with previously 
published work where they also found correlations between overexpression of CK2α and 
CK2β, and decreased patient survival {64,66}. We hope to find more patient survival 
data to give  a better understanding CK2 levels and prognosis in differing cancers.  
Our study emphasizes the potential of assessing CK2 transcript expression for 
diagnosis, and overall patient survival. However, it is important for the connection 
between CK2 transcript and protein expression to be elucidated, and how they interplay 
with the development of cancer. Understanding the interactions between the different 
CK2 genes is also important, as their levels change depending on cancer type. This could 
be important in uncovering the role of CK2 in different cancers. From there, therapy 
targeted at CK2 can be tailored towards the expression and action of CK2 in the different 
cancers.  
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The literature also showed that CK2 activity were not studied thoroughly in some 
forms of cancer. For example there was very limited information on CK2 activity in 
mesothelioma and little to no information in Hodgkin’s lymphoma. These are both cancer 
types that can and should be explored in order to discern the function CK2 in these 
cancers.    
Table 17. – Overall trends of CK2 mRNA expression levels in the differing 
types of cancers. Cancer types organized by CK2 transcript levels, beginning 
with overexpression and ending with downregulation based on Oncomine data. 
 CK2α CK2β CK2α’ CK2αP 
Bladder Up Up Up N/A 
Cervical Up Up Up N/A 
Head and neck Up Up Up N/A 
Kidney Up Up Up N/A 
Leukemia ALL (T-cell) Up Up Up N/A 
Non-Hodgkin Lymphoma 
High grade 
Up Up Up N/A 
Liver Up Up N/A N/A 
Mesothelioma Up Up N/A N/A 
Gastric Up Up Up/Down Up 
Melanoma Up Up Up/Down N/A 
Leukemia AML Up Up/Down Up Up 
Brain and CNS Up Up/Down Down N/A 
Myeloma Up/Down Up N/A N/A 
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Leukemia ALL (B-Cell) Up/Down Up Up N/A 
Leukemia CLL Down Up/Down Up N/A 
Esophageal Down Down Up/Down Down 
Non-Hodgkin Lymphoma 
Low grade 
Down Down Down N/A 
Testicular Down Down Down Down 
Leukemia HCL  N/A N/A Down N/A 
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